We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?
Read MoreHide Full Article
The Cooper Companies’ (COO - Free Report) first-quarter fiscal 2019 results are scheduled to release on Mar 5, after market close.
The company expects to gain from segmental growth in the quarter.
Fiscal Q4 Results at a Glance
In the last reported quarter, the company reported earnings of $2.87 per share, missing the Zacks Consensus Estimate by 3%. However, earnings increased 8.3% on a year-over-year basis.
The California-based specialty medical device company reported revenues worth $651.5 million, surpassing the Zacks Consensus Estimate of $645.8 million. On a year-over-year basis, revenues improved 16%.
Which Way Are Q1 Estimates Trending?
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $618.5 million, reflecting year-over-year growth of 4.8%. The same for earnings is pegged at $2.50, showing a year-over-year decline of 10.4%.
Cooper Companies reports revenues through two major segments — CooperVision (CVI) and CooperSurgical (CSI).
CVI’s Toric and Multifocal lenses, which make Cooper Companies a stalwart in the soft contact lenses market, are expected to drive fiscal first-quarter results. Additionally, CSI’s Surgical and Fertility product portfolio can fuel growth.
Notably, in the last reported quarter, CVI accounted for 73.8% of net revenues. The segment’s revenues totaled $480.6 million, up 10% on a pro forma basis and 9% year over year.
Additionally, in the last reported quarter, CSI accounted for 26.2% of net sales. Revenues at the segment came in at $170.9 million, up 5% at pro forma and 40% year over year.
It is encouraging to note that for 2019, the company expects CVI revenues within $1,940 million and $1,980 million. The same from CSI are anticipated within $660-$680 million.
Cooper Companies expects fiscal 2019 revenues within $2,600-$2,660 million. The mid-point of $2,630 million lies below the Zacks Consensus Estimate of $2.64 billion.
The company also expects adjusted earnings per share between $11.30 and $11.70. The midpoint of $11.50 is below the Zacks Consensus Estimate of $11.55.
What Does Our Model Predict?
Our quantitative model indicates a positive earnings surprise for Cooper Companies. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. This is exactly the case here.
Earnings ESP: The Earnings ESP for Cooper Companies is +0.76%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cooper Companies carries a Zacks Rank #3.
Other Stocks With a Favorable Combination
Here are a few stocks, which per our model, also have the right combination of elements to post earnings beat this quarter:
Cara Therapeutics, Inc. (CARA - Free Report) has an Earnings ESP of 11.36% and a Zacks Rank #2.
Chico’s FAS, Inc. has an Earnings ESP of 2.17% and a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?
The Cooper Companies’ (COO - Free Report) first-quarter fiscal 2019 results are scheduled to release on Mar 5, after market close.
The company expects to gain from segmental growth in the quarter.
Fiscal Q4 Results at a Glance
In the last reported quarter, the company reported earnings of $2.87 per share, missing the Zacks Consensus Estimate by 3%. However, earnings increased 8.3% on a year-over-year basis.
The California-based specialty medical device company reported revenues worth $651.5 million, surpassing the Zacks Consensus Estimate of $645.8 million. On a year-over-year basis, revenues improved 16%.
Which Way Are Q1 Estimates Trending?
For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $618.5 million, reflecting year-over-year growth of 4.8%. The same for earnings is pegged at $2.50, showing a year-over-year decline of 10.4%.
The Cooper Companies, Inc. Price and EPS Surprise
The Cooper Companies, Inc. Price and EPS Surprise | The Cooper Companies, Inc. Quote
Factors at Play
Cooper Companies reports revenues through two major segments — CooperVision (CVI) and CooperSurgical (CSI).
CVI’s Toric and Multifocal lenses, which make Cooper Companies a stalwart in the soft contact lenses market, are expected to drive fiscal first-quarter results. Additionally, CSI’s Surgical and Fertility product portfolio can fuel growth.
Notably, in the last reported quarter, CVI accounted for 73.8% of net revenues. The segment’s revenues totaled $480.6 million, up 10% on a pro forma basis and 9% year over year.
Additionally, in the last reported quarter, CSI accounted for 26.2% of net sales. Revenues at the segment came in at $170.9 million, up 5% at pro forma and 40% year over year.
It is encouraging to note that for 2019, the company expects CVI revenues within $1,940 million and $1,980 million. The same from CSI are anticipated within $660-$680 million.
Cooper Companies expects fiscal 2019 revenues within $2,600-$2,660 million. The mid-point of $2,630 million lies below the Zacks Consensus Estimate of $2.64 billion.
The company also expects adjusted earnings per share between $11.30 and $11.70. The midpoint of $11.50 is below the Zacks Consensus Estimate of $11.55.
What Does Our Model Predict?
Our quantitative model indicates a positive earnings surprise for Cooper Companies. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. This is exactly the case here.
Earnings ESP: The Earnings ESP for Cooper Companies is +0.76%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cooper Companies carries a Zacks Rank #3.
Other Stocks With a Favorable Combination
Here are a few stocks, which per our model, also have the right combination of elements to post earnings beat this quarter:
AZUL SA (AZUL - Free Report) has an Earnings ESP of 7.22% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics, Inc. (CARA - Free Report) has an Earnings ESP of 11.36% and a Zacks Rank #2.
Chico’s FAS, Inc. has an Earnings ESP of 2.17% and a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>